Related references
Note: Only part of the references are listed.DrugMAP: molecular atlas and pharma-information of all drugs
Fengcheng Li et al.
NUCLEIC ACIDS RESEARCH (2023)
Editorial overview: An initiative toward Ebolavirus disease (EVD) free world: An edited special anti-infective issue on Ebola virus disease
Elijah I. Ohimain et al.
CURRENT OPINION IN PHARMACOLOGY (2022)
DrugVirus.info 2.0: an integrative data portal for broad-spectrum antivirals (BSA) and BSA-containing drug combinations (BCCs)
Aleksandr Ianevski et al.
NUCLEIC ACIDS RESEARCH (2022)
Stopping pandemics before they start: Lessons learned from SARS-CoV-2
Aled M. Edwards et al.
SCIENCE (2022)
Therapeutic Role of Neutralizing Antibody for the Treatment against SARS-CoV-2 and Its Emerging Variants: A Clinical and Pre-Clinical Perspective
Manojit Bhattacharya et al.
VACCINES (2022)
Leveraging lessons learned from the COVID-19 pandemic for HIV
Thomas Calder et al.
COMMUNICATIONS MEDICINE (2022)
Use of subcutaneous tocilizumab in patients with COVID-19 pneumonia
Maria Mazzitelli et al.
JOURNAL OF MEDICAL VIROLOGY (2021)
RNA-dependent RNA polymerase: Structure, mechanism, and drug discovery for COVID-19
Yi Jiang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2021)
Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options
Obireddy Sreekanth Reddy et al.
CHEMBIOCHEM (2021)
Therapeutics development for Ebola virus disease: A recent scenario
Chiranjib Chakraborty
CURRENT OPINION IN PHARMACOLOGY (2021)
Mechanism of SARS-CoV-2 polymerase stalling by remdesivir
Goran Kokic et al.
NATURE COMMUNICATIONS (2021)
SARS-CoV-2 protein drug targets landscape: a potential pharmacological insight view for the new drug development
Chiranjib Chakraborty et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2021)
Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial
Zarir F. Udwadia et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)
Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP
Katerina Naydenova et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies
Chiranjib Chakraborty et al.
FRONTIERS IN PHARMACOLOGY (2021)
Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication
Jack P. K. Bravo et al.
MOLECULAR CELL (2021)
Interface-based design of the favipiravir-binding site in SARS-CoV-2 RNA-dependent RNA polymerase reveals mutations conferring resistance to chain termination
Aditya K. Padhi et al.
FEBS LETTERS (2021)
The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials
Soheil Hassanipour et al.
SCIENTIFIC REPORTS (2021)
Favipiravir, an anti-influenza drug against life-threatening RNA virus infections
Kimiyasu Shiraki et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More
Abinit Saha et al.
ARCHIVES OF MEDICAL RESEARCH (2020)
Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19
Abinit Saha et al.
ARCHIVES OF MEDICAL RESEARCH (2020)
Favipiravir, an antiviral for COVID-19?
Eric A. Coomes et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency
Calvin J. Gordon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir
Wanchao Yin et al.
SCIENCE (2020)
COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients
Chiranjib Chakraborty et al.
JOURNAL OF MEDICAL VIROLOGY (2020)
SARS-CoV-2 RNA polymerase as target for antiviral therapy
Luigi Buonaguro et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2020)
A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19
Yohei Doi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19
Rudra P. Saha et al.
FRONTIERS IN PHARMACOLOGY (2020)
Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series
Dian Fu et al.
CRITICAL CARE (2020)
COVID-19 pandemic: Lessons learned and future directions
Rohit C. Khanna et al.
INDIAN JOURNAL OF OPHTHALMOLOGY (2020)
Ebola virus disease: Recent advances in diagnostics and therapeutics
Supriya Jagga et al.
ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE (2019)
PDBsum: Structural summaries of PDB entries
Roman A. Laskowski et al.
PROTEIN SCIENCE (2018)
MOLEonline: a web-based tool for analyzing channels, tunnels and pores (2018 update)
Lukas Pravda et al.
NUCLEIC ACIDS RESEARCH (2018)
Mutagenesis in Norovirus in Response to Favipiravir Treatment
Christopher Ruis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
DynOmics: dynamics of structural proteome and beyond
Hongchun Li et al.
NUCLEIC ACIDS RESEARCH (2017)
Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
Yousuke Furuta et al.
PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES (2017)
T-705 (Favipiravir) suppresses tumor necrosis factor a production in response to influenza virus infection: A beneficial feature of T-705 as an anti-influenza drug
T. Tanaka et al.
ACTA VIROLOGICA (2017)
Distinct Effects of T-705 (Favipiravir) and Ribavirin on Influenza Virus Replication and Viral RNA Synthesis
Evelien Vanderlinden et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea
Daouda Sissoko et al.
PLOS MEDICINE (2016)
Virtual screening of the inhibitors targeting at the viral protein 40 of Ebola virus
V. Karthick et al.
INFECTIOUS DISEASES OF POVERTY (2016)
Ebola eradication may need wider partnership
Govindasamy Agoramoorthy et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2014)
Favipiravir (T-705), a novel viral RNA polymerase inhibitor
Yousuke Furuta et al.
ANTIVIRAL RESEARCH (2013)
Favipiravir (T-705) inhibits in vitro norovirus replication
J. Rocha-Pereira et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
LigPlot+: Multiple Ligand-Protein Interaction Diagrams for Drug Discovery
Roman A. Laskowski et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2011)
Computer-aided drug design platform using PyMOL
Markus A. Lill et al.
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2011)
T-705 (favipiravir) activity against lethal H5N1 influenza A viruses
Maki Kiso et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Efficacy of orally administered T-705 on lethal avian influenza a (H5N1) virus infections in mice
Robert W. Sidwell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)